{"product_id":"anti-pkc-delta-prkcd-rabbit-monoclonal-antibody-bha21008444","title":"Anti-PKC delta PRKCD Rabbit Monoclonal Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eThis product is an anti-PRKCD antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone IHD-16; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC, ICC, IF (as provided in the source record). Boster Bio Anti-PKC delta PRKCD Rabbit Monoclonal Antibody catalog # M00822. Tested in WB, IHC, ICC\/IF applications. This antibody reacts with Human, Mouse, Rat.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e PRKCD (Protein kinase C delta type).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Monoclonal; clone IHD-16; isotype Rabbit IgG.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost:\u003c\/strong\u003e Rabbit.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human,Mouse,Rat (confirm in your model system with appropriate controls).\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThis description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003ePRKCD (protein: Glycogen synthase kinase-3 beta (gsk3b)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine\/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor- initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses. Negatively regulates B cell proliferation and also has an important function in self- antigen induced B cell tolerance induction. Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1\/Btf to trigger BCLAF1-mediated p53\/TP53 gene transcription and apoptosis. In response to oxidative stress, interact with and activate CHUK\/IKKA in the nucleus, causing the phosphorylation of p53\/TP53. In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53\/TP53. In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1\/S and G2\/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)- induced inhibition of cell cycle progression at G1\/S phase by up- regulating the CDK inhibitor CDKN1A\/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2\/M DNA damage checkpoint activation. Can protect glioma cells from the apoptosis induced by TNFSF10\/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1. Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro- survival pathways, including NF-kappa-B, AKT1 and MAPK1\/3 (ERK1\/2). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl- phenylalanine (fMLP)-treated cells, is required for NCF1 (p47- phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by phosphorylation and activation of NCF1 or inly through MAPK1\/3 (ERK1\/2) signaling pathways. May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA. In collagen-induced platelet aggregation, acts a negative regulator of filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation. Downstream of PAR1, PAR4 and CD36\/GP4 receptors, regulates differentially platelet dense granule secretion; acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36\/GP4-mediated granule release. Phosphorylates MUC1 in the C- terminal and regulates the interaction between MUC1 and beta- catenin. The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (By similarity). . Reported cellular localization context: Cytoplasm. Cytoplasm, perinuclear region. Nucleus. Endoplasmic reticulum. Mitochondrion. Cell membrane; Peripheral membrane protein. Tissue expression notes (as provided): Ubiquitous. .\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eResearch context keywords from the source record include: Cancer,Oncoproteins\/Suppressors,Tumor Suppressors.\u003c\/li\u003e\n\u003cli\u003eCurrent studies often focus on connecting target abundance\/localization to pathway perturbations across models, tissues, and cell states.\u003c\/li\u003e\n\u003cli\u003eQuantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eWestern blotting (WB):\u003c\/strong\u003e assess relative target abundance across samples, treatments, or time-points.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunohistochemistry (IHC):\u003c\/strong\u003e evaluate spatial distribution of target-positive staining in tissue architecture.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunofluorescence\/ICC (IF\/ICC):\u003c\/strong\u003e visualize subcellular localization patterns and cell-to-cell heterogeneity.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWorkflow ideas (metafield): Validate PRKCD antibody specificity using KO\/KD control samples (WB\/IF\/IHC as appropriate), Detect PRKCD expression by Western blot in cell or tissue lysates, Detect PRKCD in FFPE tissue sections by immunohistochemistry, Localize PRKCD by immunofluorescence\/immunocytochemistry in cultured cells\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eConsider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.\u003c\/li\u003e\n\u003cli\u003eApparent molecular weight may vary by sample type and processing (observed MW: 78 kDa; calculated MW: 77505 MW).\u003c\/li\u003e\n\u003cli\u003eControl concepts: include appropriate negative controls (e.g., isotype, KO\/KD samples) and orthogonal validation when feasible.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eAdditional product details (from the source record)\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight (observed):\u003c\/strong\u003e 78 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCellular localization (provided):\u003c\/strong\u003e Cytoplasm. Cytoplasm, perinuclear region. Nucleus. Endoplasmic reticulum. Mitochondrion. Cell membrane; Peripheral membrane protein.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTissue details (provided):\u003c\/strong\u003e Ubiquitous. .\u003c\/li\u003e\n\u003c\/ul\u003e \u003c!-- Sources (internal): - Antibodies — a laboratory manual overview — Cold Spring Harbor Protocols — https:\/\/cshprotocols.cshlp.org\/ - UniProt Knowledgebase — UniProt — https:\/\/www.uniprot.org\/ - NCBI Gene — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Antibody validation and reproducibility — Nature methods (collections) — https:\/\/www.nature.com\/collections\/ - Immunohistochemistry\/Immunofluorescence basics — NIH \/ NCBI Bookshelf — https:\/\/www.ncbi.nlm.nih.gov\/books\/ --\u003e","brand":"Boster Bio","offers":[{"title":"100 uL\/vial \/ Unconjugated","offer_id":53071937438061,"sku":"M00822","price":370.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/m00822-djir_a_12304658_f0005_c.jpg?v=1772618372","url":"https:\/\/www.ebiohippo.com\/products\/anti-pkc-delta-prkcd-rabbit-monoclonal-antibody-bha21008444","provider":"BioHippo","version":"1.0","type":"link"}